Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 998210

Development and validation of UPLC‐MS/MS method for the determination of genotoxic impurities in Ceritinib active pharmaceutical ingredient


Antolčić, Mia; Runje, Mislav; Galić, Nives; Jurković, Vedrana
Development and validation of UPLC‐MS/MS method for the determination of genotoxic impurities in Ceritinib active pharmaceutical ingredient // 26. hrvatski skup kemičara i kemijskih inženjera : Knjiga sažetaka / Galić, Nives ; Rogošić, Marko (ur.).
Zagreb: Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI), 2019. str. 128-128 (poster, domaća recenzija, sažetak, znanstveni)


CROSBI ID: 998210 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Development and validation of UPLC‐MS/MS method for the determination of genotoxic impurities in Ceritinib active pharmaceutical ingredient

Autori
Antolčić, Mia ; Runje, Mislav ; Galić, Nives ; Jurković, Vedrana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
26. hrvatski skup kemičara i kemijskih inženjera : Knjiga sažetaka / Galić, Nives ; Rogošić, Marko - Zagreb : Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI), 2019, 128-128

ISBN
978-953-6894-67-3

Skup
26. hrvatski skup kemičara i kemijskih inženjera (26HSKIKI) ; 4. simpozij Vladimir Prelog

Mjesto i datum
Šibenik, Hrvatska, 09.04.2019. - 12.04.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
Ceritinib, genotoxic impurities ; UPLC-MS/MS

Sažetak
Potential genotoxic impurities (PGIs) are impurities that have a structural alert related to genotoxicity, whereas genotoxic impurities (GTIs) are PGIs that were proved to be genotoxic during toxicological assessment [1]. Both pharmaceutical industries and regulatory agencies have recognized the importance of GTIs in human health and regulatory issues related to the presence of GTIs in new drug formulations have been released in the last decade by the European Medicines Agency and U.S. Food and Drug Administration. Current regulatory issues are also included in the Pharmaceutical Research and Manufacturing Association. Threshold of Toxicological Concern was established and refers to a threshold exposure level of 1.5 μg/day, which is considered to be associated with an acceptable risk. Ceritinib (Figure 1) is a molecule that acts as an inhibitor of anaplastic lymphoma kinase (ALK) [2]. This pharmaceutical is therefore used to treat a specific type of lung cancer. Based on the maximum daily dosage of ceritinib (750 mg), the estimated permitted level of these impurities in ceritinib API is 2 ppm/day. In this work, an accurate, selective, precise and robust method was developed and validated for the quantitative determination of four genotoxic impurities in ceritinib by high performance liquid chromatography – tandem mass spectrometry (HPLC‐MS/MS). Method was linear for four analyzed impurities in the range from 0.5 ng mL–1 to100 ng mL–1, with detection and quantification limits of 0.5 ng mL–1 and 1 ng mL– 1, respectively.

Izvorni jezik
Engleski

Znanstvena područja
Kemija



POVEZANOST RADA


Ustanove:
Prirodoslovno-matematički fakultet, Zagreb,
PLIVA HRVATSKA d.o.o.

Profili:

Avatar Url Mislav Runje (autor)

Avatar Url Nives Galić (autor)

Poveznice na cjeloviti tekst rada:

www.hdki.hr

Citiraj ovu publikaciju:

Antolčić, Mia; Runje, Mislav; Galić, Nives; Jurković, Vedrana
Development and validation of UPLC‐MS/MS method for the determination of genotoxic impurities in Ceritinib active pharmaceutical ingredient // 26. hrvatski skup kemičara i kemijskih inženjera : Knjiga sažetaka / Galić, Nives ; Rogošić, Marko (ur.).
Zagreb: Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI), 2019. str. 128-128 (poster, domaća recenzija, sažetak, znanstveni)
Antolčić, M., Runje, M., Galić, N. & Jurković, V. (2019) Development and validation of UPLC‐MS/MS method for the determination of genotoxic impurities in Ceritinib active pharmaceutical ingredient. U: Galić, N. & Rogošić, M. (ur.)26. hrvatski skup kemičara i kemijskih inženjera : Knjiga sažetaka.
@article{article, author = {Antol\v{c}i\'{c}, Mia and Runje, Mislav and Gali\'{c}, Nives and Jurkovi\'{c}, Vedrana}, year = {2019}, pages = {128-128}, keywords = {Ceritinib, genotoxic impurities, UPLC-MS/MS}, isbn = {978-953-6894-67-3}, title = {Development and validation of UPLC‐MS/MS method for the determination of genotoxic impurities in Ceritinib active pharmaceutical ingredient}, keyword = {Ceritinib, genotoxic impurities, UPLC-MS/MS}, publisher = {Hrvatsko dru\v{s}tvo kemijskih in\v{z}enjera i tehnologa (HDKI)}, publisherplace = {\v{S}ibenik, Hrvatska} }
@article{article, author = {Antol\v{c}i\'{c}, Mia and Runje, Mislav and Gali\'{c}, Nives and Jurkovi\'{c}, Vedrana}, year = {2019}, pages = {128-128}, keywords = {Ceritinib, genotoxic impurities, UPLC-MS/MS}, isbn = {978-953-6894-67-3}, title = {Development and validation of UPLC‐MS/MS method for the determination of genotoxic impurities in Ceritinib active pharmaceutical ingredient}, keyword = {Ceritinib, genotoxic impurities, UPLC-MS/MS}, publisher = {Hrvatsko dru\v{s}tvo kemijskih in\v{z}enjera i tehnologa (HDKI)}, publisherplace = {\v{S}ibenik, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font